In extended follow-up of a South African trial in HIV-unexposed infants, PCV13 1+1 schedules (primed at 6 or 14 weeks) stayed non-inferior to 2+1 for antibody levels to age 5 years; PCV10 1+1 schedules failed non-inferiority at 4 and 5 years.
RCTn = 354
Kapelus et al. Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial